column
    Expert Consensus of Initial Treatment of Unresectable Locally Advanced/Metastatic Non-Small Cell Lung Cancer
    WU Yi-long, LU Shun, CHENG Ying, CAI Xiu-yu, CHANG Jian-hua, CHEN Ming, CHEN Xiao-yuan, FAN Yun, HUANG Cheng, LIU Hui, LIU Li, LIU Xiao-qing, PAN Yi, TU Hai-yan, WANG Jie, YANG Jin-ji, ZHANG Li, ZHU Zheng-fei, ZHOU Jian-ying, ZHOU Qing, ZHOU Jia-ying, WANG Han-min,
    2020, 20(3): 129-134. DOI: 10.12019/j.issn.1671-5144.2020.03.001
    Abstract PDF
    An Interview at 2020 Chinese Lung Cancer Summit Forum
    LI Rui-na, ZHANG Yuan-dong, ZHANG Hua
    2020, 20(3): 135-144. DOI: 10.12019/j.issn.1671-5144.2020.03.002
    Abstract PDF
    Is the Spring of Small Cell Lung Cancer Immunotherapy Coming?
    CHENG Ying
    2020, 20(3): 145-148. DOI: 10.12019/j.issn.1671-5144.2020.03.003
    Abstract PDF
    Molecular Subtypes of Small Cell Lung Cancer: A New Direction for Clinical Translational Research
    LI Hui, ZHONG Yu-min
    2020, 20(3): 149-151. DOI: 10.12019/j.issn.1671-5144.2020.03.004
    Abstract PDF
    New Era of Small-Cell Lung Cancer—Immunotherapy
    FAN Yun, YU Si-zhe, SUN Yue-li
    2020, 20(3): 152-154. DOI: 10.12019/j.issn.1671-5144.2020.03.005
    Abstract PDF
    Pembrolizumab plus Etoposide and Platinum as First-Line Therapy for Small-Cell Lung Cancer: KEYNOTE-604 Study
    XU Hai-peng, LIN Gen, HUANG Jie
    2020, 20(3): 155-157. DOI: 10.12019/j.issn.1671-5144.2020.03.006
    Abstract PDF
    Durvalumab Plus Platinum-Etoposide versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer(CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial
    WU Yu-wei, ZHAO Min-fang, KE E-e
    2020, 20(3): 158-162. DOI: 10.12019/j.issn.1671-5144.2020.03.007
    Abstract PDF
    CLAT in Combination with HLA-mismatched Peripheral Blood Stem-Cell Microtransplantation for the Treatment of Refractory AML
    LIAO Hui-yu, DENG Cheng-xin, LI Min-ming, LU Ze-sheng, LAI Pei-long, LING Wei, HUANG Li-si, CHEN Xiao-mei, WANG Yu-lian, XU Zhen-zhen, HUANG Xin, LUO Cheng-wei, WU Sui-jing, DU Xin, WENG Jian-yu
    2020, 20(3): 163-168. DOI: 10.12019/j.issn.1671-5144.2020.03.008
    Abstract PDF
    Analysis of 9 389 Cases of Cyclosporine A Therapeutic Drug Monitoring Data and Their Influencing Factors
    CHEN Xiu-yun, LIN Qiu-xiong, HOU Xing-hua, HE Guo-dong, ZHANG Meng-zhen, LI Han-ping, YANG Min
    2020, 20(3): 169-173. DOI: 10.12019/j.issn.1671-5144.2020.03.009
    Abstract PDF
    Tumor-infiltrating Lymphocytes as A Predictive Factor for pCR to Neoadjuvant Treatment in Breast Cancer
    JIN Tian-en, HUANG Jia, XIE Zhi, GUO Wei-ling, YE Zhi-qing, HUANG Jian-qing, LIANG Hong-ling
    2020, 20(3): 174-180. DOI: 10.12019/j.issn.1671-5144.2020.03.010
    Abstract PDF
    Clinical Characteristics and Influencing Factors of Patients with Abnormal Pancreatic Parameters after Allogeneic Hematopoietic Stem Cell Transplantation
    WANG Jing-hua, ZENG Gao-chun, ZHANG Wei-ya, WENG Jian-yu, LING Wei, LUO Cheng-wei, ZENG Xiang-you, WU Sui-jing
    2020, 20(3): 181-185. DOI: 10.12019/j.issn.1671-5144.2020.03.011
    Abstract PDF
    Effect of PDCD7 on the Proliferation and Apoptosis of Kasumi-1 Cells
    HUANG Zou-fang, LIAO Chang-feng, YAN Zhi-min, CHEN Yi-jian
    2020, 20(3): 186-188. DOI: 10.12019/j.issn.1671-5144.2020.03.012
    Abstract PDF
    Treatment of A Patient with Brain Lesion
    CHEN Fei-li, LI Wen-yu,
    2020, 20(3): 189-192. DOI: 10.12019/j.issn.1671-5144.2020.03.013
    Abstract PDF